Difference between revisions of "Enoxaparin (Lovenox)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
m (Text replacement - "Category:Venous thromboembolism (VTE) medications" to "Category:Venous thromboembolism medications")
Line 26: Line 26:
 
[[Category:Low molecular weight heparins]]
 
[[Category:Low molecular weight heparins]]
  
[[Category:Venous thromboembolism (VTE) medications]]
+
[[Category:Venous thromboembolism medications]]
  
 
[[Category:FDA approved in 1993]]
 
[[Category:FDA approved in 1993]]

Revision as of 19:45, 27 February 2019

General information

Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 3/29/1993: Initial FDA approval: prevention of DVT following hip replacement

Also known as

  • Brand names: Axoparin, Cardinex, Clexan, Clexane, Clotinex, Cnoxane, Cutenox, Dutenox, Enclex, Enox, Enxoaealth, Enoxol, Eparin, Lmwx, Lovenox, Markparin, Microparin, Noxprin, Pariparin, Xaparin

References